Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 8M | 4M | 5M | 3M |
| Gross Profit | 4M | 8M | 1M | 2M | -12M |
| Operating Income | -12M | -11M | -35M | -35M | -42M |
| EBITDA | -11M | -10M | -17M | -17M | -19M |
| Net Income | -10M | -8M | -16M | -16M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.49
+0.00% today
1Y Change
+600.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Starpharma Holdings Limited (SPHRF) is a Healthcare stock with a market cap of $300.00M and listed on OTC. The stock last traded around $0.49 and up 600.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -40.7%, EPS growth of -19.5%, a dividend yield of 0.0%. What stands out right now is revenue -40.7%, EPS -19.5%, free cash flow +3.8% with operating margin -100.1% and ROIC -25.2%. Valuation already assumes a fairly strong business story at price/sales 21.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPHRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPHRF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPHRF Max Drawdown
-30.43%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SPHRF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.5M
-32.4% YoY
FY Net Income
-$19.7M
-22.1% YoY
Free Cash Flow
-$15.1M
-7.5% YoY
Revenue Growth
-40.7%
EPS Growth
-19.5%
Gross Margin
60.1%
Net Margin
-22.7%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 8M | 4M | 5M | 3M |
| Gross Profit | 4M | 8M | 1M | 2M | -12M |
| Operating Income | -12M | -11M | -35M | -35M | -42M |
| EBITDA | -11M | -10M | -17M | -17M | -19M |
| Net Income | -10M | -8M | -16M | -16M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15M | 23M | 35M | 50M | 61M |
| Total Assets | 25M | 37M | 52M | 66M | 73M |
| Total Liabilities | 6M | 9M | 17M | 18M | 11M |
| Shareholder Equity | 19M | 28M | 35M | 48M | 62M |
| Total Debt | 2M | 4M | 8M | 8M | 1M |
| Net Debt | -13M | -20M | -27M | -42M | -59M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15M
-12.5% YoY
Capital Expenditures
246K
+70.6% YoY
Free Cash Flow
15M
-7.5% YoY
Key ratios
Gross Margin
60.1%
Operating Margin
-100.1%
Net Margin
-22.7%
ROE
-16.0%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.